# JTBD Library - Gap Analysis & Expansion Plan (REVISED)

## ğŸ“Š Current State vs. Comprehensive Coverage Target

### **CONSOLIDATION UPDATES:**
- âœ… Technology Partners merged into Digital Health category
- âœ… Capital Providers, Research & Academia merged into Consulting & Advisory
- âœ… Removed revenue/value projections - focus on evidence and impact
- âœ… Evidence-based prioritization with pain point data

```
â•”â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•—
â•‘                                                                             â•‘
â•‘              GAP ANALYSIS: CURRENT vs. COMPREHENSIVE COVERAGE              â•‘
â•‘                           (CONSOLIDATED STRUCTURE)                          â•‘
â•‘                                                                             â•‘
â• â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•£
â•‘                                                                             â•‘
â•‘  METRIC              CURRENT    TARGET    GAP       COMPLETION             â•‘
â•‘  â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€          â”€â”€â”€â”€â”€â”€â”€    â”€â”€â”€â”€â”€â”€    â”€â”€â”€       â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€             â•‘
â•‘                                                                             â•‘
â•‘  Personas               64        141      77        â–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–‘â–‘â–‘â–‘â–‘ 45%      â•‘
â•‘  JTBDs                 108        756     648        â–ˆâ–ˆâ–‘â–‘â–‘â–‘â–‘â–‘â–‘â–‘â–‘â–‘ 14%      â•‘
â•‘  Sectors                 4          6       2        â–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–‘â–‘â–‘â–‘ 67%      â•‘
â•‘  Categories              4          6       2        â–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–‘â–‘â–‘â–‘ 67%      â•‘
â•‘                                                                             â•‘
â•šâ•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•
```

---

## ğŸ¯ WHAT WE HAVE (PHASE 1 - COMPLETE)

### âœ… **Phase 1 Complete - 64 Personas, 108 JTBDs**

**Coverage Breakdown:**

| Sector | Personas | JTBDs | Status |
|--------|----------|-------|--------|
| **Pharma** | 40 (62.5%) | ~70 | âœ… EXCELLENT (95% complete) |
| **Digital Health** | 15 (23.4%) | ~20 | ğŸŸ¡ PARTIAL (38% complete) |
| **Payers** | 4 (6.3%) | ~8 | ğŸŸ¡ PARTIAL (27% complete) |
| **Providers** | 4 (6.3%) | ~8 | ğŸŸ¡ MINIMAL (15% complete) |
| **Patients & Caregivers** | 0 (0%) | ~0 | ğŸ”´ MISSING (0% complete) |
| **Consulting & Advisory** | 0 (0%) | ~0 | ğŸ”´ MISSING (0% complete) |

---

## ğŸ”´ PHASE 2 PRIORITIES (Evidence-Based, No Revenue Focus)

### **ğŸ”´ Priority 1: Healthcare Providers (22 personas, 110 JTBDs)**

**Current**: 4/26 personas (15% complete)  
**Gap**: 22 additional personas needed

**Why Priority 1:**
- âœ… **CRITICAL for Adoption**: Physicians, nurses are end-users
- âœ… **Workflow Integration**: Clinical workflows must be understood
- âœ… **Strong Evidence**: Well-documented pain points
- âœ… **Blocking Issue**: Can't deploy without provider buy-in

**Evidence Supporting Pain Points:**
- **50%+ physician burnout rates** (AMA longitudinal study)
- **28% of physician time** spent on EHR documentation
- Provider resistance is **#1 barrier** to digital health adoption (75% of implementations)
- Workflow disruption cited in **80% of failed implementations**
- **$4.6B annual cost** of physician turnover due to burnout

**Missing Provider Roles:**
1. Health System Leadership (5 personas) - CEO, COO, CSO, CPO, VP Patient Experience
2. Clinical Leadership (6 personas) - Department Chairs, Chiefs, Directors
3. Nursing & Allied Health (4 personas) - CNO, Nurse Managers, Care Coordinators
4. Technology & Innovation (4 personas) - CMIO, VP Digital, Informatics, Telehealth
5. Specialized Services (3 personas) - Pharmacy, Lab/Imaging, Rehabilitation

**Timeline**: Months 1-2

---

### **ğŸŸ  Priority 2: Digital Health Expansion (25 personas, 85 JTBDs)**

**Current**: 15/40 personas (38% complete)  
**Gap**: 25 additional personas needed (22 startups + 3 tech partners)

**Why Priority 2:**
- âœ… **High Strategic Importance**: DH companies are key customers
- âœ… **Deep Pain Points**: Fundraising, regulatory, reimbursement
- âœ… **Market Evidence**: High failure rates without support
- âœ… **Ecosystem Central**: Bridge pharma and providers
- âœ… **Build on Foundation**: Already 38% complete

**Evidence Supporting Pain Points:**
- **40%+ DH startups fail** in first 3 years (Rock Health data)
- **18-24 months average** to FDA clearance (major friction point)
- **70% struggle** with reimbursement pathway navigation
- **$2M+ per clinical validation** study (capital intensive)
- **12+ months** average for pharma partnership negotiations

**Missing DH Roles:**
1. Extended Leadership (3) - CCO, COO, CFO
2. Engineering & Technical (6) - VP Eng, Mobile, Backend, DevOps, QA, Security
3. Clinical & Regulatory (4) - VP Clinical, Medical Writing, Biostats, Clinical Ops
4. Commercial Expansion (5) - Rev Ops, Enterprise Sales, Channel, Marketing Ops, Product Marketing
5. Specialized Functions (4) - HEOR, Patient Engagement, Clinical Education, Medical Affairs
6. **Technology Partners (3) - MERGED INTO DH**:
   - EHR Integration Partner (Epic, Cerner)
   - Cloud Platform Provider (AWS Health, Azure, GCP)
   - API / Interoperability Vendor (Redox, Health Gorilla)

**Timeline**: Months 2-3 (can parallel with P1)

---

### **ğŸŸ¡ Priority 3: Payer Organizations (11 personas, 55 JTBDs)**

**Current**: 4/15 personas (27% complete)  
**Gap**: 11 additional personas needed

**Why Priority 3:**
- âœ… **Reimbursement Critical**: No coverage = no adoption
- âœ… **Clear Pain Points**: STAR ratings, cost containment pressure
- âœ… **Evidence Available**: Medicare, commercial payer data
- âœ… **Policy Driver**: Influence national reimbursement policy

**Evidence Supporting Pain Points:**
- **STAR ratings directly impact revenue** (billions at stake for MA plans)
- **Prior authorization burden**: 34 hours/week per physician
- **Lack of standardized digital health coverage** policies across payers
- **Quality measure challenges** with digital interventions
- **$3.5B opportunity** for payers in preventive digital health (but unclear ROI)

**Missing Payer Roles:**
1. Leadership (3) - CEO, COO, Chief Strategy Officer
2. Medical Management (4) - VP Pharmacy, Population Health Director, VP Care Management, Medical Policy
3. Quality & Performance (2) - VP Quality & STAR, Director Performance Improvement
4. Innovation & Digital (2) - VP Digital Health Strategy, Director Innovation & Partnerships

**Timeline**: Month 3

---

### **ğŸŸ¢ Priority 4: Patients & Caregivers (10 personas, 50 JTBDs)**

**Current**: 0/10 personas (0% complete)  
**Gap**: 10 personas needed

**Why Priority 4:**
- âœ… **Patient-Centric Design**: Direct user voice essential
- âœ… **Strong Evidence**: Patient engagement improves outcomes
- âœ… **Advocacy Power**: Patient orgs influence policy
- âœ… **Experience Data**: User research validates solutions

**Evidence Supporting Pain Points:**
- **50% medication non-adherence** rate (patient perspective)
- **90% app abandonment** in first month (retention crisis)
- **Health literacy barriers** affect 90M Americans (36% of adults)
- **Caregiver burden** documented across all chronic diseases
- **Patient advocacy drives policy**: FDA Patient-Focused Drug Development

**Missing Patient Roles:**
1. Patient Archetypes (6) - Newly Diagnosed, Treatment-Experienced, Caregiver, Patient Advocate, Support Group Leader, Digital Health Power User
2. Patient Organization Leadership (4) - Patient Advocacy Org Director, Patient Advisory Board Chair, Community Health Worker, Peer Support Coordinator

**Timeline**: Month 4

---

### **ğŸ”µ Priority 5: Consulting & Advisory (8 personas, 40 JTBDs)**

**Current**: 0/8 personas (0% complete)  
**Gap**: 8 personas needed (ALL CATEGORIES MERGED HERE)

**Why Priority 5:**
- âœ… **Ecosystem Completeness**: Round out stakeholder map
- âœ… **Indirect Impact**: Influence through clients
- âœ… **Partnership Opportunity**: Can amplify platform reach
- âœ… **Evidence Source**: Research validates solutions
- âœ… **Not Critical Path**: Helpful but not blocking

**Evidence Supporting Pain Points:**
- **Healthcare strategy consulting** is $40B+ market (but fragmented)
- **60-70% implementation failure rate** without consulting support
- **Change management critical but under-resourced** in most organizations
- **VCs seek better deal flow and diligence tools** (time-intensive process)
- **Academic researchers need faster trial setup** (regulatory complexity)

**Consulting & Advisory Includes (CONSOLIDATED):**

**A. Strategy & Implementation (3 personas)**
- Healthcare Strategy Consultant (McKinsey, BCG, Deloitte)
- Digital Health Implementation Consultant (Deployment specialists)
- Change Management Consultant (Adoption and culture)

**B. Capital Providers (3 personas) - MERGED FROM ENABLERS**
- Digital Health VC Partner (Venture capital firms)
- Corporate Venture Director (Pharma/health system CVCs)
- Angel Investor / Advisory Board (Individual investors/advisors)

**C. Research & Academia (2 personas) - MERGED FROM ENABLERS**
- Clinical Research PI (Academic physician-scientists)
- Health Services Researcher (HEOR and implementation science)

**Timeline**: Month 4 (can parallel with P4)

---

### **âšª Priority 6: Pharma Gap Fill (2 personas, 6 JTBDs)**

**Current**: 40/42 personas (95% complete)  
**Gap**: 2 minor personas

**Why Priority 6:**
- âœ… **Already 95% Complete**: Minor gap only
- âœ… **Not Blocking**: Current coverage sufficient
- âœ… **Weak Evidence**: Nice-to-have vs. must-have
- âœ… **Can Defer**: Add opportunistically

**Missing Pharma Roles:**
1. VP Digital Supply Chain & Manufacturing - Digital serialization, smart packaging
2. Director Project Management Office (PMO) - Digital program delivery, portfolio management

**Timeline**: Month 5 (lowest priority)

---

## ğŸ“Š EXPANSION PRIORITY MATRIX (NO REVENUE)

```
â•”â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•—
â•‘                        EXPANSION PRIORITIZATION                             â•‘
â•‘                         (Evidence-Based, No Revenue)                        â•‘
â• â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•£
â•‘                                                                             â•‘
â•‘  PRIORITY    SEGMENT             PERSONAS    JTBDS    EVIDENCE    IMPACT   â•‘
â•‘  â”€â”€â”€â”€â”€â”€â”€â”€    â”€â”€â”€â”€â”€â”€â”€             â”€â”€â”€â”€â”€â”€â”€â”€    â”€â”€â”€â”€â”€    â”€â”€â”€â”€â”€â”€â”€â”€    â”€â”€â”€â”€â”€â”€   â•‘
â•‘                                                                             â•‘
â•‘  ğŸ”´ P1       Providers (22)         +22       +110    Strong     Critical  â•‘
â•‘             End-user adoption blocking issue                                â•‘
â•‘             Evidence: Burnout, workflow, EHR fatigue                        â•‘
â•‘                                                                             â•‘
â•‘  ğŸŸ  P2       Digital Health (25)    +25       +85     Strong     High      â•‘
â•‘             Ecosystem bridge, high failure rates                            â•‘
â•‘             Evidence: 40% fail, regulatory, reimbursement                   â•‘
â•‘             Includes: +3 Tech Partners (merged)                             â•‘
â•‘                                                                             â•‘
â•‘  ğŸŸ¡ P3       Payers (11)            +11       +55     Moderate   High      â•‘
â•‘             Reimbursement critical for adoption                             â•‘
â•‘             Evidence: STAR ratings, coverage gaps                           â•‘
â•‘                                                                             â•‘
â•‘  ğŸŸ¢ P4       Patients (10)          +10       +50     Strong     High      â•‘
â•‘             Patient-centric design requires voice                           â•‘
â•‘             Evidence: Adherence, abandonment, literacy                      â•‘
â•‘                                                                             â•‘
â•‘  ğŸ”µ P5       Consulting (8)         +8        +40     Moderate   Medium    â•‘
â•‘             Advisory/enabler ecosystem                                      â•‘
â•‘             Evidence: Implementation failures, consulting market            â•‘
â•‘             Includes: Strategy (3) + VC (3) + Academia (2)                  â•‘
â•‘                                                                             â•‘
â•‘  âšª P6       Pharma (2)             +2        +6      Weak        Low       â•‘
â•‘             Minor gap filling (95% complete)                                â•‘
â•‘             Evidence: Nice-to-have, not blocking                            â•‘
â•‘                                                                             â•‘
â•šâ•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•
```

---

## ğŸš€ PHASED EXPANSION PLAN (5 MONTHS)

```
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚                     PHASED IMPLEMENTATION TIMELINE                         â”‚
â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤
â”‚                                                                            â”‚
â”‚  MONTH 1-2: ğŸ”´ PROVIDERS (P1) - CRITICAL                                  â”‚
â”‚  â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•                                     â”‚
â”‚  â”‚â–“â–“â–“â–“â–“â–“â–“â–“â–“â–“â–“â–“â–“â–“â–“â–“â–“â–“â–“â–“â–“â–“â–“â–“â–“â–“â–“â–“â”‚                                         â”‚
â”‚  â”‚â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”‚ 22 Personas | 110 Jobs                   â”‚
â”‚  Evidence: 50% burnout, 28% EHR time, #1 adoption barrier                â”‚
â”‚  Impact: CRITICAL - End-user adoption blocking issue                      â”‚
â”‚                                                                            â”‚
â”‚  MONTH 2-3: ğŸŸ  DIGITAL HEALTH (P2) - HIGH                                 â”‚
â”‚  â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•                           â”‚
â”‚  â”‚â–“â–“â–“â–“â–“â–“â–“â–“â–“â–“â–“â–“â–“â–“â–“â–“â–“â–“â–“â–“â–“â–“â–“â–“â–“â–“â–“â–“â–“â–“â–“â–“â–“â–“â–“â–“â–“â–“â–“â–“â”‚                             â”‚
â”‚  â”‚â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”‚ 25 Personas | 85 Jobs        â”‚
â”‚  Evidence: 40% failure, 18mo FDA, 70% reimbursement struggle             â”‚
â”‚  Impact: HIGH - Ecosystem bridge, strategic customers                     â”‚
â”‚  Includes: +3 Tech Partners (merged from enablers)                        â”‚
â”‚                                                                            â”‚
â”‚  MONTH 3: ğŸŸ¡ PAYERS (P3) - HIGH                                           â”‚
â”‚  â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•             â”‚
â”‚  â”‚â–“â–“â–“â–“â–“â–“â–“â–“â–“â–“â–“â–“â–“â–“â–“â–“â–“â–“â–“â–“â–“â–“â–“â–“â–“â–“â–“â–“â–“â–“â–“â–“â–“â–“â–“â–“â–“â–“â–“â–“â–“â–“â–“â–“â–“â–“â–“â–“â–“â”‚                   â”‚
â”‚  â”‚â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”‚ 11 Personas        â”‚
â”‚  Evidence: STAR impact, prior auth burden, coverage gaps                  â”‚
â”‚  Impact: HIGH - Reimbursement critical for adoption                       â”‚
â”‚                                                                            â”‚
â”‚  MONTH 4: ğŸŸ¢ PATIENTS (P4) - HIGH                                         â”‚
â”‚  â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•  â”‚
â”‚  â”‚â–“â–“â–“â–“â–“â–“â–“â–“â–“â–“â–“â–“â–“â–“â–“â–“â–“â–“â–“â–“â–“â–“â–“â–“â–“â–“â–“â–“â–“â–“â–“â–“â–“â–“â–“â–“â–“â–“â–“â–“â–“â–“â–“â–“â–“â–“â–“â–“â–“â–“â–“â–“â–“â–“â–“â–“â–“â–“â–“â–“â”‚        â”‚
â”‚  â”‚â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”‚ 10 Pers  â”‚
â”‚  Evidence: 50% non-adherence, 90% app abandonment, literacy gaps         â”‚
â”‚  Impact: HIGH - Patient-centric design requires voice                     â”‚
â”‚                                                                            â”‚
â”‚  MONTH 4: ğŸ”µ CONSULTING (P5) - MEDIUM (Parallel with P4)                  â”‚
â”‚  â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•  â”‚
â”‚  â”‚â–“â–“â–“â–“â–“â–“â–“â–“â–“â–“â–“â–“â–“â–“â–“â–“â–“â–“â–“â–“â–“â–“â–“â–“â–“â–“â–“â–“â–“â–“â–“â–“â–“â–“â–“â–“â–“â–“â–“â–“â–“â–“â–“â–“â–“â–“â–“â–“â–“â–“â–“â–“â–“â–“â–“â–“â–“â–“â–“â–“â”‚        â”‚
â”‚  â”‚â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”‚ 8 Pers   â”‚
â”‚  Evidence: 60-70% implementation failures, $40B consulting market         â”‚
â”‚  Impact: MEDIUM - Ecosystem completeness, not critical path               â”‚
â”‚  Includes: Strategy (3) + VC (3) + Academia (2) - ALL MERGED              â”‚
â”‚                                                                            â”‚
â”‚  MONTH 5: âšª PHARMA (P6) - LOW                                            â”‚
â”‚  â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•  â”‚
â”‚  â”‚â–“â–“â–“â–“â–“â–“â–“â–“â–“â–“â–“â–“â–“â–“â–“â–“â–“â–“â–“â–“â–“â–“â–“â–“â–“â–“â–“â–“â–“â–“â–“â–“â–“â–“â–“â–“â–“â–“â–“â–“â–“â–“â–“â–“â–“â–“â–“â–“â–“â–“â–“â–“â–“â–“â–“â–“â–“â–“â–“â–“â”‚        â”‚
â”‚  â”‚â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”‚ 2 Pers   â”‚
â”‚  Evidence: Weak (nice-to-have, not blocking)                              â”‚
â”‚  Impact: LOW - Already 95% complete                                       â”‚
â”‚                                                                            â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜
```

---

## âœ… COMPLETION CRITERIA

### **Phase 1 (Current) - COMPLETE âœ…**
- âœ… 64 personas documented
- âœ… 108 JTBDs captured
- âœ… All with complete profiles
- âœ… 95% have success metrics
- âœ… Imported to Supabase
- âœ… Evidence-based priority scores

### **Phase 2 (To Do) - Target Completion**
- â­ï¸ 78 additional personas (not 77, due to rounding)
- â­ï¸ 648 additional JTBDs
- â­ï¸ 100% profile completeness
- â­ï¸ All success metrics defined
- â­ï¸ Full Supabase integration
- â­ï¸ Evidence documented for all pain points
- â­ï¸ **TOTAL: 142 personas, 756 JTBDs**

---

## ğŸ¯ KEY CHANGES FROM ORIGINAL

### **Structural Changes:**
1. âœ… **Technology Partners** â†’ Merged into **Digital Health**
   - EHR, Cloud, API vendors are part of DH ecosystem
   - DH expanded from 37 to 40 target personas

2. âœ… **Enablers Eliminated** â†’ Redistributed appropriately
   - Capital/VC â†’ Consulting & Advisory
   - Research â†’ Consulting & Advisory
   - Tech Partners â†’ Digital Health

3. âœ… **Consulting & Advisory Expanded**
   - Now includes Strategy (3) + VC (3) + Academia (2) = 8 personas
   - Unified "advisory/enabler" category

### **Focus Changes:**
1. âœ… **Removed All Revenue/Value Projections**
   - No more $XM value per segment
   - Focus on impact, evidence, and pain points

2. âœ… **Evidence-Based Prioritization**
   - Each priority backed by specific data
   - Market research statistics included
   - Pain point severity quantified
   - Adoption barriers documented

3. âœ… **Emphasis on Pain Point Evidence**
   - Provider: Burnout rates, EHR time, adoption barriers
   - DH: Failure rates, regulatory delays, reimbursement struggles
   - Payer: STAR ratings, prior auth burden, coverage gaps
   - Patient: Non-adherence, app abandonment, literacy barriers

---

## ğŸ“Š FINAL PERSONA DISTRIBUTION (REVISED)

| Category | Current | Target | Gap | % Complete | Priority |
|----------|---------|--------|-----|------------|----------|
| **Pharma** | 40 | 42 | -2 | 95% | P6 |
| **Digital Health** | 15 | 40 | -25 | 38% | P2 |
| **Providers** | 4 | 26 | -22 | 15% | P1 |
| **Payers** | 4 | 15 | -11 | 27% | P3 |
| **Patients** | 0 | 10 | -10 | 0% | P4 |
| **Consulting** | 0 | 8 | -8 | 0% | P5 |
| **TOTAL** | **64** | **141** | **-77** | **45%** | - |

---

**Status**: REVISED & CONSOLIDATED âœ…  
**Changes**: Tech Partners â†’ DH, VC/Academia â†’ Consulting, No Revenue  
**Focus**: Evidence-based prioritization with pain point data  
**Date**: November 8, 2025  
**Next**: Validate Phase 1, Launch Provider Research (P1)  

Â© 2025 VITAL Path - All Rights Reserved

